Prialt® (Ziconotide) - CAM 965HB
Background
FDA-Approved Indication: Prialt (ziconotide) is indicated for the management of severe chronic pain in adult patients for whom intrathecal (IT) therapy is warranted and who are intolerant of or refractory to other treatment options, such as systemic analgesics, adjunctive therapies, or intrathecal morphine.
Policy (Criteria)
Initial Authorization Criteria
Prialt may be considered medically necessary when all of the following criteria are met:
1. Diagnosis of severe chronic pain examples include, but are not limited to:
- Cancer-related pain
- Neuropathic pain
- Failed back surgery syndrome
- Complex regional pain syndrome (CRPS)
- Chronic intractable non-malignant pain
- Spinal cord injury-related pain
2. Patient does not have a history of psychosis
3. Patient does not have a contraindication to intrathecal analgesia examples include:
- Active systemic infection
- Active meningitis
- Local infection at the catheter insertion site
- Conditions preventing implantation or management of an intrathecal drug delivery system
4. Medication will be administered intrathecally via an appropriate intrathecal infusion system
5. Patient has tried and had an inadequate response, intolerance, or contraindication to at least one of the following:
- Intrathecal morphine
- Other systemic pain medications (e.g., opioids, anticonvulsants, antidepressants)
- Adjunctive pain therapies (e.g., physical therapy, nerve blocks, spinal cord stimulation, non-opioid analgesics)
6. Prescribed by or in consultation with a pain management specialist, anesthesiologist, neurologist, neurosurgeon, palliative care specialist, or physician experienced in intrathecal drug delivery systems
Authorization Duration: 6 months
Reauthorization Criteria
Prialt may be reauthorized when all of the following criteria are met:
1. Documentation of a positive clinical response to therapy evidence may include one or more of the following:
- Clinically meaningful reduction in pain severity from baseline
- Improvement in functional status or activities of daily living
- Reduction in rescue analgesic use
- Reduction in systemic opioid requirements
- Improvement in quality of life measures
- Improved sleep, mobility, or participation in daily activities
2. Patient continues to tolerate therapy without severe neuropsychiatric adverse effects examples include:
- No evidence of psychosis
- No severe cognitive impairment attributable to therapy
- No severe confusion or hallucinations requiring discontinuation
3. Continued administration by or in consultation with a physician experienced in intrathecal pain management
Authorization Duration: 12 months
References
- Prialt® (ziconotide) Prescribing Information. Jazz Pharmaceuticals, Inc. Current prescribing information.
- Rauck RL, Wallace MS, Leong MS, et al. A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults With Severe Chronic Pain. Journal of Pain and Symptom Management. 2006;31(5):393-406.
- Wallace MS, Charapata SG, Fisher R, et al. Intrathecal Ziconotide in the Treatment of Chronic Nonmalignant Pain. Neuromodulation. 2008;11(2):63-70.
- Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines. Neuromodulation. 2017;20(2):96-132.
- Deer TR, Pope JE, Hanes MC, et al. Polyanalgesic Consensus Conference 2016 Guidelines on Intrathecal Drug Delivery. Neuromodulation. 2017;20(2):96-132.
- American Society of Regional Anesthesia and Pain Medicine (ASRA). Guidance on intrathecal drug delivery systems.
- National Comprehensive Cancer Network (NCCN). Adult Cancer Pain Guidelines. Current version.
- International Association for the Study of Pain (IASP). Chronic pain management principles and treatment guidance.
Coding Section
| Code |
Number |
Description |
| CPT |
62369 |
Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill |
|
|
62370 |
Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); with reprogramming and refill (requiring skill of a physician or other qualified healthcare professional) |
| HCPCS |
J2278 |
Injection, ziconotide, 1 mcg |
Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each Policy. They may not be all-inclusive.
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.
"Current Procedural Terminology © American Medical Association. All Rights Reserved"
History From 2026 Forward
| 10/01/2026 |
New Policy |